Jim Cramer says buy, the stock pops. He trashes a name, it tanks. The real question isn’t what he said about Marvell (MRVL) and Bausch Health (BHC). It’s whether you should treat those calls as gospel—or as contrarian signals. Here’s the blunt answer: Cramer is better at spotting narratives than nailing entry points. And in…